Good points Sanfran.

I also feel that if zen3694 shows early positive signs in the metastatic castration resistent prostate cancer it will support their early research and MOA findings. Anything positive for these very sick patients will be noticed. I believe this will have a halo effect on RVX. It will also boost interest in the epigenetic approach in BET inhibition developed by RVX and Zenith.

After reading BDAZs summaries of the Zenith and RVX presentations at the New York Academy of Sciences I got even more excited by the scientific and medical implications.

That being said the share price clearly suggests there is an awareness or credibility gap in either the science or the business or both.

IMHO there is a tremendous amount going on behind the scenes on a number of fronts and we may get some pleasant surprises. The silence on the business side may be because it is required!

The question I would like to put out to readers is "Why did Don hire a VP of Investor Relations now?". He must have specific reasons for this timing. Perhpas a Zenith IPO is close at hand and he needs the VP IR to help with the promotion of the IPO?

I'd like to hear some ideas on this because it does not seem to me to be a necessary position at this stage unless some big things are about to happen.

Looking forward to some thoughts.

Toinv